Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
暂无分享,去创建一个
M. Vidali | M. Ciaccio | R. V. Giglio | B. Lo Sasso | C. Scazzone | C. M. Gambino | G. Bivona | L. Agnello | Anna Maria Ciaccio
[1] S. Y. Kim,et al. Global, regional, and national incidence and mortality of COVID-19 in 237 countries and territories, January 2022: a systematic analysis for World Health Organization COVID-19 Dashboard , 2022, Life Cycle.
[2] P. Olliaro. An integrated understanding of long-term sequelae after acute COVID-19 , 2021, The Lancet Respiratory Medicine.
[3] G. Lippi,et al. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination , 2021, Diagnostics.
[4] F. Ferrara,et al. Brief review of the mRNA vaccines COVID-19 , 2021, Inflammopharmacology.
[5] M. Barbagallo,et al. Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19 , 2021, Laboratory medicine.
[6] M. Dimopoulos,et al. Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine , 2021, American journal of hematology.
[7] B. Combadière,et al. Strategies for Immunomonitoring after Vaccination and during Infection , 2021, Vaccines.
[8] Khalid J. Alzahrani,et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms , 2021, Viruses.
[9] H. Schaal,et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination , 2021, medRxiv.
[10] T. Piccoli,et al. COVID-19 and Alzheimer’s Disease , 2021, Brain sciences.
[11] Ji-min Cao,et al. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development , 2020, Frontiers in Cellular and Infection Microbiology.
[12] C. Colomba,et al. Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG , 2020, Biochemia medica.
[13] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[14] S. Kang,et al. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses , 2020, Infection, Genetics and Evolution.
[15] M. Ciaccio,et al. Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19) , 2020, Diagnosis.